SpyGlass Pharma
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
27061 Aliso Creek Rd Ste 100, Aliso Viej...Phone Number
(949) 284-6904Website
www.spyglasspharma.comRevenue
-Industry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
3
1
1
2
About SpyGlass Pharma
The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues. Patients in the first-in-human study will continue to be followed over time, and the Company plans to share 24-month follow up data at the American Academy of Ophthalmology meeting later this year. SpyGlass completed enrollment in a Phase I/II study in the United States to investigate the safety and efficacy of its platform in a larger patient pool. SpyGlass looks forward to working closely with the U.S. Food and Drug Administration (FDA) to advance the program through Phase III clinical trials and ultimately to commercial approval.Explore more
SpyGlass Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SpyGlass Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when SpyGlass Pharma launches new products
Check if SpyGlass Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on SpyGlass Pharma recently announced quarterly report
SpyGlass Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once SpyGlass Pharma has new funding data
Click to see if SpyGlass Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at SpyGlass Pharma
Check out if SpyGlass Pharma is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined SpyGlass Pharma as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
SpyGlass Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SpyGlass Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SpyGlass Pharma.
SpyGlass Pharma financials insights
Gather financial insights about SpyGlass Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series C
$90M
2025
Series D
$75M
2026
IPO
$150M
SpyGlass Pharma Tech Stack
A closer look at the technologies used by SpyGlass Pharma
Most Recent Scoops
Hiring Plans
SpyGlass Pharma has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Clinical Trial Development, Biotechnology, Medical Affairs, Ophthalmology, Patient Identification and Matching, Integrated Delivery Systems, and Glaucoma.
Hiring Plans
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Hiring Plans
Hiring Plans
SpyGlass Pharma News & Media
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. Mr. Pinder brings over 20 years of commercial launch experience in ophthalmology, focused on building, launching, and evolving significant brands, notably in the buy-and-bill specialty pharma model. At SpyGlass Pharma, he will build and lead the marketing function for theSpyGlass Pharma to Participate in Upcoming Investor Conferences
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences:SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercialization Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercializationSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the first quarter ended March 31, 2026.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SpyGlass Pharma
Sign Up For FreeTo access detailed company insights
The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues. Patients in the first-in-human study will continue to be followed over time, and the Company plans to share 24-month follow up data at the American Academy of Ophthalmology meeting later this year. SpyGlass completed enrollment in... Read More
